Design and results of PERSIST-1 trial of pacritinib for myelofibrosis by Ruben Mesa
Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia
Chronic Lymphocytic Leukemia
Chronic Myeloid Leukemia
Diffuse Large B-Cell Lymphoma
View expert index
View all diseases
View all trials
View all medicines
EMMA Vienna 2017
View upcoming conferences
View previous conferences
A decade of advances in multiple myeloma and unanswered questions
Vincent Rajkumar, MD, from the Mayo Clinic, Rochester, MN discusses the questions that remain at the heart of multiple myeloma…
What is the potential of daratumumab in combination therapy for myeloma?
Torben Plesner, MD, from the Vejle Hospital and University of Southern Denmark, Vejle, Denmark, discusses the efficacy and mechanism of…
Advances in multiple myeloma treatment over the last years
Vincent Rajkumar, MD, from the Mayo Clinic, Rochester, MN, discusses the advances of the last few years in multiple myeloma…
Research on HDACs for multiple myeloma: studying immunological effects and resistance models
Enrique M. Ocio, MD, PhD, from the University Hospital of Salamanca, Spain discusses his work on histone deacetylase inhibitors (HDACs)…
The ongoing debate for treating multiple myeloma
Xavier Leleu, MD, PhD of Poitiers University Hospital, Poitiers, France discusses the factors that influence the choice of continuous therapy…
HDACs in multiple myeloma: potential benefits in maintenance phase
Enrique M. Ocio, MD, PhD, from the University Hospital of Salamanca, Spain discusses optimizing the use of histone deacetylase inhibitors…
What does the future treatment landscape of myeloma look like?
Michele Cavo, MD, from the Bologna University School of Medicine, Bologna, Italy, discusses ongoing research for multiple myeloma (MM) and…
Engaging in social media is extremely helpful to discuss research
Saad Usmani, MD, FACP, from the Levine Cancer Institute, Charlotte, NC, speaks about why he uses social media to engage…
Can venetoclax be used to treat multiple myeloma (MM)?
Philippe Moreau, MD, from the University Hospital of Nantes, Nantes, France, speaks about the potential of venetoclax in multiple myeloma…
Which is the best combination therapy in relapsed and refractory multiple myeloma?
Meletios Dimopoulos, MD, from the Athens School of Medicine, Athens, Greece, discusses combination therapies for relapsed and refractory myeloma treatment…
Sign up for the latest news and videos
Is CLL curable today?
How far are we from a cure for CLL?
Mechanism of action of venetoclax (ABT-199) and its side effects
Myeloma 2016: Panel discussion on novel treatments
Highlights from the International Workshop of the German CLL Study Group